Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adriana Parise Compri has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Concurrent Circulation of Viral Agents in Pediatric Patients Presenting with Respiratory Illness and Diarrheal Symptoms in Metropolitan Region of São Paulo, Brazil, 2021

    by Adriana Luchs, Natanael Sutikno Adiwardana, Leonardo Cecilio da Rocha, Ellen Viana, Simone Guadagnucci, Adriana Parise, Vanessa Cristina Martins Silva, Lais Sampaio de Azevedo, Raquel Guiducci, Yasmin França, et al.

    Pneumonia and diarrhea are the leading causes of death in children under 5 globally, worsened by viral infections. This study investigates viral agents in children ≤ 3 years with respiratory illness and diarrhea in Metropolitan Region of São Paulo, Brazil, during spring 2021. Twenty paired samples (oropharyngeal swab and feces) were tested using in-house qPCR for HBoV and HAdV, RT-qPCR for RVA, EV, PeV-A, and NoV, and a commercial RT-qPCR kit for SARS-CoV-2, Flu A/B, and RSV. HAstV was detected with conventional nested (RT)-PCR. Positive samples were sequenced for molecular characterization and phylogenetic analysis. Seven viruses were identified: HBoV, NoV, HAdV, PeV-A, EV, RSV, and Flu A. HBoV and NoV were detected in 75% of cases, with co-infection in 65% of patients, indicating their involvement in the gastro-respiratory illness. Genotyping of HBoV (HBoV-1), NoV (GII.4_Sydney[P16], GII.2[P16], and GII.4_Sydney[P31]), EV (Coxsackievirus A6), HAdV (species C, type 6), and PeV-A (genotype 1) showed local virus diversity. Phylogenetic analysis indicated no ongoing community outbreak, with distinct clusters observed. The findings highlight the overlap of respiratory and enteric diseases, revealing local viral diversity and high exposure to enteric viruses. This underscores the challenges in differential diagnosis and the need for syndromic surveillance.


  • Emerging zooanthroponotic risks: Detection of the human norovirus GII.4 Sydney[P31] strain in a domestic dog in Brazil

    by Lais Sampaio de Azevedo, Vanessa Cristina Martins Silva, Raquel Guiducci, Simone Guadagnucci, Fernanda Faria Costa, Monique Beerens Abdul Ghani, Ricardo Duarte Lopes, Antonio Charlys da Costa, Lia Cunha, Marcilio Figueredo Lemos, et al.

  • Open Access

    Hepatite C: evolução do diagnóstico e tratamento

    by Gabriela Nardini Allarcon, Marcilio Figueiredo Lemos, Vanessa Cristina Martins Silva, Clovis Roberto Abe Constantino, Adriana Parise Compri

    A hepatite C é uma das principais causas de doença hepática crônica, cirrose e carcinoma hepatocelular. Estima-se que 58 milhões de pessoas tenham infecção crônica com cerca de 1,5 milhão de novas infecções por ano. Em 2016, a OMS estipulou a meta de eliminar as hepatites virais até 2030, reduzindo em 90% as novas infecções e em 65% as mortes. Este relato de experiência se propõe a apresentar os avanços no diagnóstico e tratamento da hepatite C no período de 2000 a 2023 e discutir os desafios ainda presentes para atingir a meta da OMS. O diagnóstico da Hepatite C envolve o uso de técnicas sorológicas para a triagem e de biologia molecular para confirmação do diagnóstico, além de avaliar a eficácia do tratamento. O único tratamento disponível até 2011 era a combinação de Interferon alfa peguilado e Ribavirina. A disponibilidade e a evolução das drogas antivirais de ação direta a partir de 2011 contribuíram com o avanço no tratamento, apresentando alta eficácia, período mais curto de terapia, menos contraindicações e poucos efeitos adversos. Mesmo com esses avanços, apenas 20% das pessoas que vivem com Hepatite C no mundo foram diagnosticadas e 7% receberam tratamento. Conclui-se por tanto que para atingir a meta da OMS será necessário um diagnóstico acessível e rápido, no local de atendimento, além de campanhas de triagem e tratamento em massa como parte do programa de vigilância nacional desse agravo.


  • Open Access

    Hepatitis A, B and C prevalence among transgender women and travestis in five Brazilian capitals between 2019-2021

    by Regina Célia Moreira, Maria Amélia de Sousa Mascena Veras, Carolina Amianti, Daniel Jason McCartney, Vanessa Cristina Martins Silva, Marcilio Figueiredo Lemos, Adriana Parise Compri, Elaine Lopes de Oliveira, Katia Cristina Bassichetto, Andréa Fachel Leal, et al.

    To estimate the prevalence and factors associated with hepatitis A, B, and C in transgender women and travestis's networks, in 5 regions of Brazil.


  • Open Access

    Hepatitis B Prevalence among Men Who Have Sex with Men in Brazil

    by Ana Rita C. Motta-Castro, Lígia Kerr, Carl Kendall, Rosa S. Mota, Mark Drew C. Guimarães, Andréa Fachel Leal, Edgar Merchan-Hamann, Inês Dourado, Maria Amélia Veras, Ana Maria de Brito, et al.

    Hepatitis B virus (HBV) is a global public health problem and requires specific prevention actions, particularly focusing on the key populations, such as men who have sex with men (MSM). We aimed at assessing the prevalence of HBV infection, among MSM, in a multicity study in Brazil. In 2016, we conducted a survey using a respondent-driven sampling methodology in 12 Brazilian cities. Rapid tests (RT) were performed on 3178 samples from those MSM. Positive results were tested for HBV DNA and sequenced. If negative for HBV DNA, samples were tested for serological markers. The prevalence rate of HBV exposure and clearance was 10.1% (95% CI: 8.1–12.6), and 1.1% (95%; CI: 0.6–2.1) were confirmed to be HBsAg-positive. Of those samples tested for anti-HBs (n = 1033), only 74.4% presented a serological profile analogous to that elicited by hepatitis B vaccination. Among HBsAg-positive samples (n = 29), 72.4% were HBV DNA-positive, and from these, 18 were sequenced. HBV genotypes A, F, and G were found in 55.5%, 38.9%, and 5.6%, respectively. This study indicates high prevalence rates of MSM HBV exposure and a low positivity index for the serological marker of HBV vaccine immunity. These findings may contribute to the discussion of strategies to prevent hepatitis B and reinforce the importance of promoting HBV vaccination in this key population.


  • Open Access

    Detection of Hepatitis E Virus Genotype 3 in Feces of Capybaras (Hydrochoeris hydrochaeris) in Brazil

    by Lia Cunha, Adriana Luchs, Lais S. Azevedo, Vanessa C. M. Silva, Marcilio F. Lemos, Antonio C. Costa, Adriana P. Compri, Yasmin França, Ellen Viana, Fernanda Malta, et al.

    Hepatitis E virus (HEV) is an emerging zoonotic pathogen associated with relevant public health issues. The aim of this study was to investigate HEV presence in free-living capybaras inhabiting urban parks in São Paulo state, Brazil. Molecular characterization of HEV positive samples was undertaken to elucidate the genetic diversity of the virus in these animals. A total of 337 fecal samples were screened for HEV using RT-qPCR and further confirmed by conventional nested RT-PCR. HEV genotype and subtype were determined using Sanger and next-generation sequencing. HEV was detected in one specimen (0.3%) and assigned as HEV-3f. The IAL-HEV_921 HEV-3f strain showed a close relationship to European swine, wild boar and human strains (90.7–93.2% nt), suggesting an interspecies transmission. Molecular epidemiology of HEV is poorly investigated in Brazil; subtype 3f has been reported in swine. This is the first report of HEV detected in capybara stool samples worldwide.